West Pharmaceutical Services, Inc. (NYSE:WST) is included among the 14 Best Dividend Growth Stocks to Buy and Hold in 2026. KeyBanc Sees Injectable GLP-1s Driving Ongoing Demand for WST KeyBanc sees limited risk to oral weight loss drugs through 2030, even with the potential approval of an oral version of Wegovy. In a research note, the firm said oral GLP-1 adoption is likely to stay capped in both the near and longer term, despite new products entering the market. KeyBanc estimates the oral version of W ...